767-775
Original Article
Tumor specific cytotoxicity of glucosylceramide
Hirosuke Oku, Sawitree Wongtangtintharn, Hironori Iwasaki, Masashi Inafuku and Masayuki Shimatani, et al.
777-787
Original Article
Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib
Alex Hemeryck, Rita Geerts, Johan Monbaliu, Stephan Hassler and Tom Verhaeghe, et al.
789-797
Original Article
Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure–activity relationship
Kazuhiro Katayama, Kazuto Masuyama, Sho Yoshioka, Hitomi Hasegawa and Junko Mitsuhashi, et al.
799-809
Original Article
Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors
Feng Guo, Stephen P. Letrent and Amarnath Sharma
811-819
Original Article
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer
Wei Peng Yong, Apurva A. Desai, Federico Innocenti, Jacqueline Ramirez and Dale Shepard, et al.
821-829
Original Article
Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts
Jonathan C. Low, Kishor M. Wasan, Ladan Fazli, Andy Eberding and Hans Adomat, et al.
831-839
Original Article
Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent
Ritu Aneja, Neerupma Dhiman, Jyoti Idnani, Anshumali Awasthi and Sudershan K. Arora, et al.
841-849
Original Article
Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro
Hairong Song, Marina Vita, Hatem Sallam, Ramin Tehranchi and Christina Nilsson, et al.
851-861
Original Article
Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial
S. Danson, M. Ranson, O. Denneny, J. Cummings and T. H. Ward
863-869
Original Article
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer
Jong Gwang Kim, Sang Kyun Sohn, Hong Suk Song, Ki-Young Kwon and Young Rok Do, et al.
871-882
Original Article
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors
Muhammad Wasif Saif, Sandra Sellers, Mao Li, Wei Wang and Linda Cusimano, et al.
883-889
Original Article
O
4-benzylfolic acid inactivates
O
6-alkylguanine-DNA alkyltransferase in brain tumor cell lines
Stewart P. Johnson, Barton A. Kamen, Darell D. Bigner and Henry S. Friedman
891-897
Original Article
Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of gallium–porphyrin complex ATX-70
Nagahiko Yumita, Nobuo Okuyama, Kazuaki Sasaki and Shin-ichiro Umemura
899-905
Original Article
Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents
Jyoti B. Patel, Aakanksha Khandelwal, Pankaj Chopra, Venkatesh D. Handratta and Vincent C. O. Njar
907-914
Original Article
Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model
Vessela Vassileva, Justin Grant, Raquel De Souza, Christine Allen and Micheline Piquette-Miller
915-919
Short Communication
A pharmacokinetic study on Z-(±)-2-(1-benzylindole-3-yl-methylene)azabicyclo[2.2.2]octane-3-ol; a novel radio-sensitization agent
Abeer M. Al-Ghananeem, Zaineb F. Albayati, Ahmad Malkawi, Vijayakumar N. Sonar and Michael L. Freeman, et al.
921-924
Short Communication
Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma
J. Cummings, M. Ranson, F. Butt, D. Moore and C. Dive